MaliTuberculosis profile
Population  2014 17 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.8 (1.3–2.4) 11 (7.9–14)
Mortality (HIV+TB only) 0.4 (0.3–0.52) 2.4 (1.8–3)
Prevalence  (includes HIV+TB) 16 (8.3–25) 91 (49–148)
Incidence  (includes HIV+TB) 9.8 (9.5–10) 58 (56–59)
Incidence (HIV+TB only) 0.71 (0.64–0.78) 4.1 (3.8–4.5)
         
Case detection, all forms (%) 59 (57–61)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.3–3.1) 17 (4.4–30)
MDR-TB cases among notified pulmonary
TB cases
75 (13–140) 57 (15–99)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 3 804   165
Pulmonary, clinically diagnosed 632   0
Extrapulmonary 1 208    
       
Total new and relapse 5 809    
Previously treated, excluding relapses 167    
Total cases notified 5 976    
Among 5 646 new and relapse cases:
69 (1%) cases aged under 15 years; male:female ratio: 2.0
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 294 (8%) 12 (4%) 294
Laboratory-confirmed RR-/MDR-TB cases     40
Patients started on MDR-TB treatment ***     33
TB/HIV 2014 Number (%)
TB patients with known HIV status 2 563 (43)
HIV-positive TB patients 367 (14)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 265 (72)
HIV-positive TB patients on antiretroviral therapy (ART) 367 (100)
HIV-positive people screened for TB 7 724  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (74) 5 810
Previously treated cases, excluding relapse, registered in 2013 (76) 191
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (67) 12
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 0.4
Culture (per 5 million population) 0.9
Drug susceptibility testing (per 5 million population) 0.9
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions) 2.9
% Funded domestically 27%
% Funded internationally 55%
% Unfunded 19%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-02-13 Data: www.who.int/tb/data